title: NCCN Guidelines Update for Multiple Myeloma.
abstract: The updated NCCN Guidelines for Multiple Myeloma feature several changes in the diagnosis and management of this disease. Criteria for treatment initiation have been broadened, new staging has been recommended, and new classes of agents and combinations are included as recommended treatment. Monoclonal antibodies are among the expanded therapeutic choices, along with a histone deacetylase inhibitor and third-generation proteosome inhibitor, and there is excitement about exploring new immune-based approaches.
authors.affiliation: Presented by Kenneth C. Anderson, MD, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
mesh_terms: D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis / Q000628:therapy